期刊文献+

有效引导肝细胞生成素分泌的外源信号肽的确定 被引量:2

Selection of the exogenous signal peptide that conducts the secretion of hepatopoietin
下载PDF
导出
摘要 目的:寻找能有效引导肝细胞生成素(HPO)分泌的外源信号肽序列,构建高效分泌HPO的真核表达载体,以提高蛋白的分泌量。方法:将不同的信号肽编码序列通过PCR方法与HPO基因融合,克隆到真核表达载体中,构建HPO真核表达载体,通过脂质体介导瞬时转染COS-7细胞,采用Western blotting方法检测HPO的分泌情况。结果:采用了白细胞介素-1受体拮抗剂的信号肽、一种人工信号肽和小鼠抗体kappa链信号肽,分别构建HPO分泌型表达载体,通过Western blotting检测显示,前2种信号肽引导HPO分泌的效率很低,只有来自小鼠抗体kappa链的信号肽能够高效引导HPO从细胞中分泌出来,分泌蛋白以二聚体形式存在,大小为30kD。结论:成功构建了高分泌型HPO真核表达载体,为进行肝纤维化的基因治疗奠定了基础。 AIM: To look for a suitable signal peptide which may effectively conduct hepatopoietin (HPO) secretion, various recombinant eukaryotic expression vectors were constructed. METHODS: Different exogenous signal sequences were spliced with HPO cDNA by PCR, and the spliced genes were cloned into eukaryotic expression plasmids. The different recombinants were respectively tansfected into COS - 7 cells by Lipofectamine 2000 method and the secretion of HPO was analyzed by Western blotting. RESULTS : Western blotting analysis indicated that the signal peptides from interleukin - 1 receptor antagonist (IL -lra) and an artifical signal peptide did not secret HPO directly and effectively, but the signal peptide from murine Ig kappa secreted HPO directly with great efficiency. The molecular weight of the secreted HPO was 30 kD, which means that the secreted HPO existed in homodimer. CONCLUSION: Secreted recombinant expression plasmid is. successful constructed. The result may pave the way for the gene therapy of hepatic fibrosis.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2008年第7期1390-1393,共4页 Chinese Journal of Pathophysiology
基金 北京市自然科学基金资助项目(No.7042046)
关键词 肝细胞生成素 真核表达 信号肽 Hepatopoietin Eukaryotic expression Signal peptide
  • 相关文献

参考文献8

二级参考文献78

共引文献82

同被引文献56

  • 1陈晓宇,陈晓蓉,李俊,张荣宜,齐威琴.帕金森病大鼠中脑腹侧被盖区多巴胺能神经元的改变[J].郑州大学学报(医学版),2005,40(6):1064-1066. 被引量:3
  • 2梁亚杰,李淑蓉,苏炳银.MPTP致小鼠黑质致密部多巴胺能神经元损伤及定量研究[J].第三军医大学学报,2006,28(5):454-457. 被引量:4
  • 3Petroske E, Meredith G E, Callen S, et al. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment [ J ]. Neuroscience, 2001, 106 (3) : 589 - 601.
  • 4Gorbatyuk O S, Li S, Sullivan L F, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease[ J]. Proc Natl Acad Sci U S A, 2008, 105(2) : 763 -768.
  • 5Amer D A, Irvine G B, El-Agnaf O M. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders[J]. Exp Brain Res, 2006, 173 (2) : 223 -233.
  • 6Ogawa N, Hirose Y, Ohara S, et al. A simple quantitative bradykinesia test in MPTP-treated mice[ J ]. Res Commun Chem Pathol Pharmacol, 1985, 50(3) : 435 -441.
  • 7Matsuura K, Kabuto H, Makino H, et al. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion[ J]. J Neurosci Methods, 1997, 73( 1 ) : 45 -48.
  • 8Schenk D, Barbour R, Dunn W, et al. hmnunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [J]. Nature, 1999, 400(6740): 173-177.
  • 9Games D, Bard F, Grajeda H, et al. Prevention and reduction of AD- type pathology in PDAPP mice immunized with A beta 1-42 [ J ]. Ann N Y Acad Sci, 2000, 920:274 -284.
  • 10Luthi-Carter R. Progress towards a vaccine for Huntington ' s disease [J]. Mol Ther, 2003, 7(SPt 1): 569-570.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部